TRINITY BIOTECH PLC (TRIB) Form 424B3 — Jun 18, 2026
Trinity Biotech plc filed a prospectus supplement for the resale of up to 33,752,429 American Depositary Shares by selling shareholders, representing 675,048,580 ordinary shares, with a last reported sale price of $0.5799 per ADS on June 17, 2026. The filing incorporates a Form 6-K reporting Q1 2026 financial results, highlighting a 43% year-over-year revenue increase to $10.8 million driven by strong demand for its TrinScreen HIV and haemoglobin product lines. Operational improvements were evident as gross margin expanded to 35.4% from 25.2% in the prior year, while the net loss narrowed to $4.4 million compared to $8.8 million in Q1 2025.
Key figures
- Eps
- 0
- Revenue
- $10.8m
- Net Income
- -$4.4m
- Revenue Yoy
- 43%
- Offering Price
- $0.5799
- Shares Offered
- 33752429
- Adjusted ebitda
- -$1.1m
- Hiv test orders
- 2 million
- Q1 2025 gross margin
- 25.2%
- Q1 2026 gross margin
- 35.4%
- Q1 2026 rapid hiv sales
- $3.7m
- Q1 2026 hemoglobin sales
- $3.3m
- Q1 2026 trinscreen sales
- $2.3m
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.